The teratological effect of benzolamide, a new carbonic anhydrase inhibitor.
D000014:Abnormalities, Drug-Induced / Q000209:etiology*; D000136:Acid-Base Equilibrium / Q000187:drug effects; D000818:Animals; D002257:Carbonic Anhydrase Inhibitors / Q000009:adverse effects*; D005260:Female; D005333:Fetus / Q000032:analysis; D005865:Gestational Age; D006571:Heterocyclic Compounds / Q000009:adverse effects*; D006863:Hydrogen-Ion Concentration; D007279:Injections, Subcutaneous; D008099:Liver / Q000032:analysis; D008431:Maternal-Fetal Exchange; D009132:Muscles / Q000032:analysis; D011188:Potassium / Q000032:analysis / Q000652:urine; D011191:Potassium Deficiency; D011247:Pregnancy; D011248:Pregnancy Complications; D051381:Rats; D012272:Ribs / Q000002:abnormalities*; D013449:Sulfonamides / Q000008:administration & dosage / Q000032:analysis; D013806:Theophylline / Q000494:pharmacology; D013830:Thiadiazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000032:analysis
D002257:Carbonic Anhydrase Inhibitors; D006571:Heterocyclic Compounds; D013449:Sulfonamides; D013830:Thiadiazoles; D013806:Theophylline; D011188:Potassium